Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022215043> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W3022215043 endingPage "2852" @default.
- W3022215043 startingPage "2841" @default.
- W3022215043 abstract "Lenvatinib has become the most commonly prescribed first-line (1L) agent for the treatment of radioactive iodine-refractory differentiated thyroid cancer (RAI-r DTC) since its approval in 2015. With no real-world studies describing clinical outcomes of 1L lenvatinib and subsequent therapy, the current study aimed to assess treatment sequencing and related clinical outcomes in patients treated with 1L lenvatinib in the USA We conducted a multisite, retrospective chart review of US patients with a diagnosis of RAI-r DTC who had initiated 1L therapy with lenvatinib from January 1, 2016 through May 31, 2017 with follow-up through October 17, 2018. Physicians completed electronic case report forms for two patient cohorts: patients still receiving 1L lenvatinib (cohort 1) and those who had initiated second-line (2L) therapy prior to data cutoff (cohort 2). Real-world objective response rate (ORR) was assessed for both cohorts. Progression-free survival (PFS) and overall survival (OS) were assessed for cohort 2. A total of 252 patients met the study criteria with 71 in cohort 1 and 181 in cohort 2. Patients were predominantly female, had papillary DTC, and had lung metastases. The ORR was 64.8% for cohort 1 and 53.6% for cohort 2. In cohort 2, median PFS from 1L lenvatinib initiation was 14.0 months (95% CI 12.7–15.0). Second-line treatments included sorafenib (49.7%), cabozantinib (19.3%), and other targeted/chemotherapy/immuno-oncology agents. The ORR in 2L therapy was 15.5%. For cohort 2, the 12-, 18-, and 24-month OS from initiation of 1L lenvatinib was 92.8%, 81.5%, and 66.9%, respectively. In this first real-world examination of clinical effectiveness of 1L lenvatinib and subsequent therapy among patients in the US, the results demonstrated that treatment with 1L lenvatinib followed by another 2L therapy may deliver a clinical benefit, thus allowing a number of potential 2L options following 1L lenvatinib for patients with RAI-r DTC." @default.
- W3022215043 created "2020-05-13" @default.
- W3022215043 creator A5006893148 @default.
- W3022215043 creator A5014595568 @default.
- W3022215043 creator A5029365217 @default.
- W3022215043 creator A5037074954 @default.
- W3022215043 creator A5050866878 @default.
- W3022215043 creator A5084076545 @default.
- W3022215043 date "2020-05-07" @default.
- W3022215043 modified "2023-10-18" @default.
- W3022215043 title "Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States" @default.
- W3022215043 cites W1967792499 @default.
- W3022215043 cites W1984185945 @default.
- W3022215043 cites W1990196512 @default.
- W3022215043 cites W2019607817 @default.
- W3022215043 cites W2028080080 @default.
- W3022215043 cites W2040642592 @default.
- W3022215043 cites W2040826406 @default.
- W3022215043 cites W2087440541 @default.
- W3022215043 cites W2116542352 @default.
- W3022215043 cites W2152382138 @default.
- W3022215043 cites W2168076926 @default.
- W3022215043 cites W2587955949 @default.
- W3022215043 cites W2766426751 @default.
- W3022215043 cites W2777197634 @default.
- W3022215043 cites W2789109497 @default.
- W3022215043 cites W2920559179 @default.
- W3022215043 cites W2974520132 @default.
- W3022215043 cites W2990423583 @default.
- W3022215043 doi "https://doi.org/10.1007/s12325-020-01362-6" @default.
- W3022215043 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7467445" @default.
- W3022215043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32382946" @default.
- W3022215043 hasPublicationYear "2020" @default.
- W3022215043 type Work @default.
- W3022215043 sameAs 3022215043 @default.
- W3022215043 citedByCount "24" @default.
- W3022215043 countsByYear W30222150432020 @default.
- W3022215043 countsByYear W30222150432021 @default.
- W3022215043 countsByYear W30222150432022 @default.
- W3022215043 countsByYear W30222150432023 @default.
- W3022215043 crossrefType "journal-article" @default.
- W3022215043 hasAuthorship W3022215043A5006893148 @default.
- W3022215043 hasAuthorship W3022215043A5014595568 @default.
- W3022215043 hasAuthorship W3022215043A5029365217 @default.
- W3022215043 hasAuthorship W3022215043A5037074954 @default.
- W3022215043 hasAuthorship W3022215043A5050866878 @default.
- W3022215043 hasAuthorship W3022215043A5084076545 @default.
- W3022215043 hasBestOaLocation W30222150431 @default.
- W3022215043 hasConcept C121608353 @default.
- W3022215043 hasConcept C126322002 @default.
- W3022215043 hasConcept C143998085 @default.
- W3022215043 hasConcept C167135981 @default.
- W3022215043 hasConcept C207103383 @default.
- W3022215043 hasConcept C2776264508 @default.
- W3022215043 hasConcept C2778019345 @default.
- W3022215043 hasConcept C2778695046 @default.
- W3022215043 hasConcept C2779761222 @default.
- W3022215043 hasConcept C2781064419 @default.
- W3022215043 hasConcept C2781230642 @default.
- W3022215043 hasConcept C44249647 @default.
- W3022215043 hasConcept C71924100 @default.
- W3022215043 hasConcept C72563966 @default.
- W3022215043 hasConceptScore W3022215043C121608353 @default.
- W3022215043 hasConceptScore W3022215043C126322002 @default.
- W3022215043 hasConceptScore W3022215043C143998085 @default.
- W3022215043 hasConceptScore W3022215043C167135981 @default.
- W3022215043 hasConceptScore W3022215043C207103383 @default.
- W3022215043 hasConceptScore W3022215043C2776264508 @default.
- W3022215043 hasConceptScore W3022215043C2778019345 @default.
- W3022215043 hasConceptScore W3022215043C2778695046 @default.
- W3022215043 hasConceptScore W3022215043C2779761222 @default.
- W3022215043 hasConceptScore W3022215043C2781064419 @default.
- W3022215043 hasConceptScore W3022215043C2781230642 @default.
- W3022215043 hasConceptScore W3022215043C44249647 @default.
- W3022215043 hasConceptScore W3022215043C71924100 @default.
- W3022215043 hasConceptScore W3022215043C72563966 @default.
- W3022215043 hasIssue "6" @default.
- W3022215043 hasLocation W30222150431 @default.
- W3022215043 hasLocation W30222150432 @default.
- W3022215043 hasLocation W30222150433 @default.
- W3022215043 hasOpenAccess W3022215043 @default.
- W3022215043 hasPrimaryLocation W30222150431 @default.
- W3022215043 hasRelatedWork W1840931546 @default.
- W3022215043 hasRelatedWork W2150001950 @default.
- W3022215043 hasRelatedWork W2746560743 @default.
- W3022215043 hasRelatedWork W3084251940 @default.
- W3022215043 hasRelatedWork W3138443913 @default.
- W3022215043 hasRelatedWork W3214163464 @default.
- W3022215043 hasRelatedWork W4315485237 @default.
- W3022215043 hasRelatedWork W4364368825 @default.
- W3022215043 hasRelatedWork W4378675839 @default.
- W3022215043 hasRelatedWork W4385898854 @default.
- W3022215043 hasVolume "37" @default.
- W3022215043 isParatext "false" @default.
- W3022215043 isRetracted "false" @default.
- W3022215043 magId "3022215043" @default.
- W3022215043 workType "article" @default.